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 The lipoxin A4 receptor (FPR2/ALX) belongs to the class A 
rhodopsin G protein-coupled receptor superfamily and plays 
a role in chemotaxis and activation of phagocytes  (1) . Several 
structurally diverse agonistic ligands, including peptides and 
lipid mediators have been shown to bind to the FPR2/ALX 
 (2) . Since the discovery of serum amyloid A (SAA) as a pro-
infl ammatory ligand for FPR2/ALX, more peptides were 
identifi ed, which all mediate a pro-infl ammatory activation of 
leukocytes through FPR2/ALX  (1) . In contrast, FPR2/ALX 
can also bind anti-infl ammatory ligands, such as lipoxin A4 
(LXA4) and annexin-1  (2) . Indeed, LXA4 was shown to 
inhibit neutrophil migration, to induce chemotaxis of mono-
cytes and to promote the non-phlogistic phagocytosis of 
apoptotic neutrophils by macrophages  (2) . Thus, FPR2/ALX 
might induce anti-infl ammatory effects when pro-resolving 
mediators are present. 
 Expression of the FPR2/ALX has been observed in sev-
eral human chronic infl ammatory diseases, such as der-
matitis, rheumatoid arthritis, and severe asthma, however, 
the role of the FPR2/ALX in atherosclerosis has not been 
investigated  (3) . 
 Atherosclerosis is a multifactorial disease that is char-
acterized by chronic infl ammation at every stage with leu-
kocytes infi ltrating the arterial intima  (4) . To investigate 
the role of FPR2/ALX in atherosclerosis we screened the 
 FPR2/ALX gene for polymorphisms and analyzed whether 
the detected polymorphisms are associated with coronary 
artery disease (CAD) in a case-control study involving 497 
Caucasians  (5, 6) . We initially screened the promoter, the 
coding region and the 3 ′ region of the  FPR2/ALX gene of 
98 Caucasians for polymorphisms by DHPLC and detected 
eight variations, fi ve of which were located in the promoter 
region, one in the coding region, and two in the 3 ′ region 
(Table  1 ). Seven of these variations proved to be polymor-
phisms with minor allele frequencies between 5 % and 32 % , 
while variant c.410G > A was a private mutation. The geno-
type frequency for all polymorphisms was in agreement 
with those predicted by the Hardy-Weinberg equilibrium in 
the case-control sample. 
 This case-control sample for CAD included 259 patients 
with  > 50 % stenosis in at least one coronary artery and 238 
subjects without a history of CAD, stroke, or peripheral vas-
cular disease  (5, 6) . Written informed consent was obtained 
from all participants and the Local Ethics Committee 
approved the study. The case-control study has a power of 
25 % – 80 % to detect an OR of 1.7 for minor allele frequencies 
of 5 % – 30 % . 
 Logistic regression analysis revealed no association 
between fi ve polymorphisms of the  FPR2/ALX gene and 
CAD (Table  1 ), while the T allele of the c.-7893C > T poly-
morphism was associated with an increased risk for CAD 
(OR = 2.9; confi dence interval 1.2 – 7.1; p-value: 0.018). This 
c.-7893C > T polymorphism is located in the core promoter of 
the  FPR2/ALX gene and could therefore modify the binding 
site for a transcription factor and hence alter transcription of 
the gene  (8) . 
 To test whether the C > T transition affects the transcrip-
tional activity of the promoter, we subcloned the  FPR2/ALX 
core promoter upstream of a luciferase reporter gene and 
introduced all the variations of the minor alleles of the three 
promoter polymorphisms into individual constructs. These 
constructs were then transiently transfected into THP-1 mac-
rophages and the transcriptional activity of the different pro-
moter alleles was judged from the intensity of the luciferase 
reporter enzyme (Figure  1 , dual-luciferase reporter assay). 
None of the three polymorphisms c.-7978A > G, c.-7986A > G 
and c.-7893C > T altered the transcriptional activity of the 
 FPR2/ALX promoter in macrophages, suggesting that the 
observed association of the SNP c.-7893C > T with CAD 
was rather a chance fi nding than a real association. This is 
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supported by the skewed distribution of the homozygous TT 
genotypes between cases and controls in the study sample. 
While the TT genotype was observed to a low frequency in 
cases, this genotype was absent in controls (1.95 % vs. 0 % , 
respectively). The  FPR2/ALX haplotypes derived from the 
seven polymorphisms also showed no association with CAD. 
 Table 1  Logistic regression model predicting CAD status for cases. 
NM01005738 Allele frequency,  % Genotype controls,  % Genotype cases,  % OR 95 % CI p-Value
c.-8751A > G A: 68.6   G: 31.4 47.3/43.9/8.9 47.5/41.2/11.3 1.72 0.75 – 3.94 0.20
rs11666254
c.-8461T > G T: 68.3    G: 31.7 46.4/43.9/9.7 47.5/41.6/10.9 0.60 0.26 – 1.36 0.22
rs11670660
c.-7986A > G A: 73      G: 27 49.8/46/4.2 52.1/42/5.8 0.98 0.69 – 1.40 0.92
rs35215887
c.-7978A > G A:95        G: 5 92.4/7.6/0 89.1/9.7/1.2 1.42 0.75 – 2.68 0.29
rs35225016
c.-7893C > T C: 88.2      T: 11.8 77.2/22.8/0 77.4/20.6/1.9 2.93 1.20 – 7.13 0.02
rs56238033
c.410G > A Private mutation
c.1315A > G A: 89.1      G: 10.9 76.8/23.2/0 80.5/18.3/1.2 0.66 0.19 – 2.28 0.51
rs17695052
c.1346C > T C: 89.4       T: 10.6 77.2/22.4/0.4 81.3/17.9/0.8 0.51 0.17 – 1.58 0.24
rs17695064
 DNA extracted from EDTA-supplemented blood was genotyped by tetra-primer analysis for each variation  (7) . Association with CAD was 
analyzed by logistic regression using an additive genetic model adjusted for age and sex. p < 0.05. 
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 Figure 1  Basal transcription of the different  FPR2/ALX core pro-
moter alleles observed. 
 Luciferase expression of the four  FPR2/ALX core promoter alleles 
was determined (c.-7986A > G: A-to-G base exchange at position 
-7986; c.-7978A > G: A-to-G base exchange at position -7978; c.7893-
C > T: C-to-T base exchange at position -7893). Human THP-1 mono-
cytes were transfected with the constructs mentioned and a renilla 
control construct, differentiated into macrophages and the luciferase 
activity was measured and normalized against the activity of the 
renilla luciferase 48 h later. Results were calculated as fold induction 
over the  FPR2/ALX wild-type core promoter. All experiments were 
done in triplicate and bars indicate the means of three independent 
experiments with three plasmid preparations. Values represent fold 
induction compared to the P1-414 vector and the error bars represent 
the standard deviation ( ± SD). 
We observed six haplotypes with a frequency  > 1 % which 
summed up to 94 % of all haplotypes in the sample (data not 
shown). 
 In this study, we identifi ed seven polymorphisms in the 
promoter and in the 3 ′ region of the  FPR2/ALX gene, but 
no polymorphism was detected in the coding region of the 
gene. Such a lack of polymorphisms in the coding region of 
the  FPR2/ALX gene has previously been observed in a small 
study comparing the number of polymorphisms in the coding 
region between the  FPR2/ALX and the closely related  FPR1 
gene  (9) . This study found that the two genes originated 
from a common gene but that they had undergone markedly 
different evolutionary events since then. While seven poly-
morphisms have been detected in the coding region of the 
 FPR1 gene in this small Caucasian, Black and Asian sample, 
no polymorphism was detected in the  FPR2/ALX coding 
region in the same racial groups  (9) . Our study supports and 
expands these fi ndings, because we screened an additional 
196 Caucasian alleles and did not fi nd a polymorphism in the 
coding region of the  FPR2/ALX . Such an absence of func-
tional polymorphisms in the coding region and the lack of 
functional polymorphisms in the core promoter region sug-
gest that the  FPR2/ALX gene is highly conserved in humans 
and that it may be important for the correct function of leuko-
cytes in innate immunity. 
 In conclusion, the  FPR2/ALX gene was not associated with 
CAD in our small case-control study, however, our study 
suggests that the  FPR2/ALX gene is conserved in humans, 
since no polymorphism in the coding region and no func-
tional polymorphisms in the core promoter region have been 
identifi ed. 
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